Rite Aid gets fit with BL Body
CAMP HILL, Pa. — Rite Aid on Tuesday announced its partnership with BL Body, a collection of shape wear available exclusively in Rite Aid stores, on a sweepstakes with a first prize trip for two to the location of the reality program “The Biggest Loser.”
Rite Aid is taking sweepstake entries through Jan. 22 for the $4,000-grand prize. Second prize is a year’s membership for two to the Biggest Loser Club online weight-loss program, a $479 value.
The sweepstakes is being promoted with in-store radio and a national radio tour featuring Ashley Johnston, the runner-up to season nine who set a show all-time record for most weight loss by a woman. Johnston also is a spokeswoman for the BL Body collection of shape wear inspired by the show.
Rite Aid already has an established weight-loss heritage in the California market through its retail-clinic partnership with weight-loss clinic Lindora.
The chain provides a 12-page informational guide in stores or online at RiteAid.com packed with weight-loss tips, techniques and topics, including how to fight childhood obesity, the importance of counting calories instead of just carbohydrates or fat and how to exercise on a budget.
Rite Aid customers also can access the Rite Weight program at RiteAid.com/RiteWeightPlan. That program, created by Lindora, aims to help patients lose up to 10% of their body weight in 10 weeks with free online seminars, weight-tracking tools and daily support e-mails.
For members of its free Wellness+ customer rewards program, Rite Aid is offering discounts and rebates on healthy weight products purchased through Jan. 22. Specials include buy-one/get-one-free offers on vitamins and supplements, meal replacements and fat burners.
Par launches generic Rhythmol SR
WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical has begun shipping its version of a treatment for heart rhythm problems, the company said Monday.
Par announced the shipment of propafenone SR capsules, a treatment for atrial fibrillation in patients without structural heart disease.
The drug is a generic version of GlaxoSmithKline’s Rhythmol SR, which has annual sales of around $121 million, according to IMS Health.
As the first company to file for approval of a generic version of the drug, Par has 180 days in which to market its version in direct competition with GlaxoSmithKline’s under the terms of the Hatch-Waxman Act of 1984.
Endo’s Fortesta receives FDA approval
CHADDS FORD, Pa. — The Food and Drug Administration has approved a topical testosterone replacement therapy made by Endo Pharmaceuticals, Endo said last week.
The drug maker announced on Dec. 29 the approval of Fortesta (testosterone) gel, a treatment for men with low testosterone, which affects nearly 14 million men in the United States.
Endo said it planned to introduce Fortesta in the United States early this year.